Package Leaflet: Information for the User
Karvea 75 mg film-coated tablets
Irbesartan
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Karvea belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body that causes blood vessels to narrow, leading to an increase in blood pressure. Karvea blocks the action of angiotensin-II, relaxing the blood vessels and lowering blood pressure. Karvea slows the progression of kidney damage in patients with high blood pressure and type 2 diabetes.
Karvea is used in adult patients:
Do not take Karvea
Warnings and precautions
Tell your doctor before taking Karvea and if any of the following apply to you:
if you are going to have surgery(surgical procedure) or if you are going to be givenanesthetics
Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.
See also the information under the heading "Do not take Karvea".
If you are pregnant, think you may be pregnant, or plan to become pregnant, inform your doctor. Karvea is not recommended during the first few months of pregnancy (first trimester) and should not be taken after the third month of pregnancy, as it may harm your baby (see section "Pregnancy").
Children and adolescents
This medicine should not be used in children and adolescents as the safety and efficacy have not been fully established.
Taking Karvea with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Your doctor may need to change your dose and/or take other precautions:
If you are taking an ACE inhibitor or aliskiren (see also the information under the headings "Do not take Karvea" and "Warnings and precautions").
You may need to have blood tests if you are taking:
If you are using a type of painkiller known as non-steroidal anti-inflammatory medicines, the effect of irbesartan may be reduced.
Taking Karvea with food and drink
Karvea can be taken with or without food.
Pregnancy and breastfeeding
Pregnancy
Inform your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. Your doctor will advise you to stop taking Karvea before you become pregnant or as soon as you know you are pregnant, and will recommend an alternative blood pressure medicine. Karvea should not be taken during the first few months of pregnancy and should not be used after the third month of pregnancy, as it may harm your baby.
Breastfeeding
Inform your doctor if you are breastfeeding or plan to start breastfeeding. Your doctor may decide to give you a different treatment that is more suitable if you want to breastfeed, especially for newborns or premature babies.
Driving and using machines
Karvea is unlikely to affect your ability to drive or use machines. However, during treatment for high blood pressure, dizziness or fatigue may occasionally occur. If you experience these symptoms, consult your doctor before driving or using machines.
Karvea contains lactose. If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
Karvea contains sodium. This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
Method of administration
Karvea is taken orally. The tablets should be swallowed with a sufficient amount of liquid (e.g., a glass of water). Karvea can be taken with or without food. Try to take your daily dose at the same time each day. It is important to continue taking this medicine until your doctor tells you to stop.
The usual dose is 150 mg once daily (two tablets a day). Depending on the response to blood pressure, this dose may be increased to 300 mg once daily (four tablets a day).
In patients with high blood pressure and type 2 diabetes, the recommended maintenance dose for the treatment of kidney damage is 300 mg once daily (four tablets a day).
Your doctor may advise a lower dose, especially when starting treatment, in certain patients, such as those on hemodialysisor over 75 years of age.
The maximum blood pressure-lowering effect should be achieved within 4-6 weeks after starting treatment.
Use in children and adolescents
Karvea should not be given to children under 18 years of age. If a child swallows several tablets, contact your doctor immediately.
If you take more Karvea than you should
If you accidentally take too many tablets, contact your doctor immediately.
If you forget to take Karvea
If you accidentally miss a dose, simply take your normal dose when it is due. Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
However, some of these side effects can be serious and may require medical attention.
As with similar medicines, rare cases of skin allergic reactions (rash, urticaria) and localized swelling (in the face, lips, and/or tongue) have been reported in patients treated with irbesartan. If you think you may have a reaction of this type or experience difficulty breathing, stop takingKarveaand seek medical attention immediately.
The following side effects have been reported:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
The following side effects have been reported in clinical trials in patients treated with Karvea:
Since the marketing of Karvea, the following side effects have been reported:
Frequency not known: cannot be estimated from the available data
The following side effects have been reported: feeling dizzy, headache, altered taste, ringing in the ears, muscle cramps, muscle or joint pain, decreased number of red blood cells (anemia - symptoms may include tiredness, headaches, difficulty breathing when exercising, dizziness, and paleness), reduced number of platelets, abnormal liver function, high potassium levels in the blood, impaired kidney function, inflammation of small blood vessels, mainly in the skin area (a condition known as leucocytoclastic vasculitis), severe allergic reactions (anaphylactic shock), and low blood sugar levels. Rare cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month shown.
Do not store above 30°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
What Karvea contains
Appearance and packaging
Karvea 75 mg film-coated tablets are white or almost white, biconvex, and oval-shaped, with a heart-shaped indentation on one side and the number 2871 engraved on the other side.
Karvea 75 mg tablets are available in blister packs of 14, 28, 30, 56, 84, 90, or 98 film-coated tablets. They are also available in packs of 56 x 1 film-coated tablet containing unit-dose blisters for hospital use.
Not all pack sizes may be marketed.
Marketing authorization holder
sanofi-aventis groupe, 54 rue La Boétie, F-75008 Paris, France
Manufacturer
SANOFI WINTHROP INDUSTRIE, 1, rue de la Vierge, Ambarès & Lagrave, F-33565 Carbon Blanc Cedex, France
SANOFI WINTHROP INDUSTRIE, 30-36 Avenue Gustave Eiffel, BP 7166, F-37071 Tours Cedex 2, France
For further information, contact the local representative of the marketing authorization holder.
Belgium Sanofi Belgium Tel: +32 (0)2 710 54 00 | Luxembourg Sanofi Belgium Tel: +32 (0)2 710 54 00 (Belgium) |
Bulgaria Sanofi Bulgaria EOOD Tel: +359 (0)2 970 53 00 | Hungary SANOFI-AVENTIS Zrt. Tel: +36 1 505 0050 |
Czech Republic sanofi-aventis, s.r.o. Tel: +420 233 086 111 | Malta Sanofi S.r.l. Tel: +39 02 39394275 |
Denmark Sanofi A/S Tel: +45 45 16 70 00 | Netherlands Sanofi B.V. Tel: +31 20 245 4000 |
Germany Sanofi-Aventis Deutschland GmbH Tel: 0800 52 52 010 Tel from abroad: +49 69 305 21 131 | Norway sanofi-aventis Norge AS Tel: +47 67 10 71 00 |
Estonia Swixx Biopharma OÜ Tel: +372 640 10 30 | Austria sanofi-aventis GmbH Tel: +43 1 80 185 – 0 |
Greece Sanofi-Aventis Μονοπρ?σωπη AEBE Tel: +30 210 900 16 00 | Poland sanofi-aventis Sp. z o.o. Tel: +48 22 280 00 00 |
Spain sanofi-aventis, S.A. Tel: +34 93 485 94 00 | Portugal Sanofi - Produtos Farmacêuticos, Lda Tel: +351 21 35 89 400 |
France Sanofi Winthrop Industrie Tel: 0 800 222 555 Call from abroad: +33 1 57 63 23 23 Croatia Swixx Biopharma d.o.o. Tel: +385 1 2078 500 | Romania Sanofi Romania SRL Tel: +40 (0) 21 317 31 36 |
Ireland sanofi-aventis Ireland Ltd. Tel: +353 (0) 1 403 56 00 | Slovenia Swixx Biopharma d.o.o. Tel: +386 1 235 51 00 |
Iceland Vistor hf. Tel: +354 535 7000 | Slovakia Swixx Biopharma s.r.o. Tel: +421 2 208 33 600 |
Italy Sanofi S.r.l. Tel: 800.536389 | Finland Sanofi Oy Tel: +358 (0) 201 200 300 |
Cyprus C.A. Papaellinas Ltd. Tel: +357 22 741741 | Sweden Sanofi AB Tel: +46 (0)8 634 50 00 |
Latvia Swixx Biopharma SIA Tel: +371 6616 47 50 | United Kingdom(Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2525 |
Lithuania Swixx Biopharma UAB Tel: +370 5 236 91 40 |
Date of last revision of this leaflet:
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/